BUSINESS Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% Sunday, March 29, 2026 · novartis pharma ag Advertisement Read Original Article → Related Dispatches [CA] · Jun 27 Qualcomm: M&A Driven Growth Strategy Pays Off - Dip Buying Opportunity Ahead [CA] · Jun 27 Insurers in gainers; Goldman Sachs, Morgan Stanley among losers: week's financials wrap [US] · Jun 27 Northern California has a pediatric care crisis. We must address it now | Opinion